Tuesday, July 7, 2009

5AM Ventures raises $159M life sciences fund

By Mass High Tech staff

Video Gallery

MHT's Galen Moore: Hiring trends and opportunities

MHT's Efrain Viscarolasaga: Tech companies may have to wait for stimulus funds

MHT's Marc Songini: Researchers focus on macular degeneration

Related News

Pulmatrix pulls in $3M in new venture round [March 13, 2009]

Semprus secures $8M in Series A funds [December 11, 2008]

Hanrahan joins Pulmatrix as chief medical officer [September 18, 2008]

Clarus adds to Pearl’s Series A luster [July 7, 2008]

N.E. researchers share grants for infectious diseases [November 6, 2009]

Life sciences-focused venture capital firm 5AM Ventures has raised $159 million from 34 investors in its third fund, according to a filing with the U.S. Securities and Exchange Commission.

The seed money provider, which has offices in Waltham and Menlo Park, Calif., had listed almost $120 million in an April filing, according to a report from PE Hub. Its first fund, upon launching in 2004, was valued at $65 million, while its 2006 second fund brought in $150 million.

The 5AM Ventures website lists its managing partners as John Diekman, Scott Rocklage and Andrew Schwab. Among its investments, 5AM Ventures has backed Lexington-based biotech Pulmatrix Inc.; Cambridge-based Semprus BioSciences Corp., an antibacterial coatings biomedical company; and California firms Relypsa Inc., Pearl Therapeutics and Ambrx Inc.